New Study Links Common Joint Supplement Glucosamine to Faster Alzheimer's Progression

Key points

• Researchers analyzed deidentified health records from 2012 to 2024, finding that 8% of patients with Alzheimer's or mild cognitive impairment used glucosamine.
• Glucosamine use was linked to a 25% higher likelihood of progression from mild cognitive impairment to dementia, as well as a 25% higher mortality risk among those already diagnosed with dementia.
• Lab experiments on mice and human brain tissue showed that glucosamine increases hyperglycosylation, an abnormal process where sugar structures attach to proteins, potentially contributing to cognitive decline.
• The study does not prove that glucosamine causes dementia; it only identifies an association, and researchers note that other factors may explain the results.
• Rheumatologists caution that glucosamine has limited evidence for joint pain relief and may not be worth the potential risks for those with cognitive issues.

Background

This finding adds to a growing body of research exploring metabolic and non-amyloid factors in Alzheimer's disease. Recent studies have highlighted how disrupted 3D genome organization and hormonal changes, such as early menopause, may influence brain aging and dementia risk. While current FDA-approved drugs focus on clearing amyloid plaques, scientists are increasingly investigating metabolic pathways and inflammation as complementary targets for slowing neurodegeneration.

How outlets are covering it

ScienceDaily and UA.NEWS report the core findings from the University of Florida study, emphasizing the statistical association between glucosamine use and faster dementia progression. MedShadow Foundation provides broader context, noting that glucosamine has long lacked strong evidence for joint benefits and that the new study raises concerns about potential harm. Rheumatologists cited by MedShadow, such as Sharon Kolasinski and Kent Kwoh, caution that the observational data cannot prove causality and that glucosamine may not be worth taking given its lack of proven efficacy for osteoarthritis. Tom Appleton suggests that the association might reflect pre-existing risk factors rather than a direct effect of the supplement.

Why it matters

Millions of older adults take glucosamine for joint pain, and the study raises questions about whether this common supplement could accelerate cognitive decline in those with early memory issues. While the findings are preliminary, they highlight the need for clinical trials to determine if glucosamine should be avoided by patients with mild cognitive impairment or dementia. The research also underscores the importance of understanding metabolic pathways in Alzheimer's disease, potentially opening new avenues for treatment beyond traditional amyloid and tau targets.

What to watch

Researchers call for controlled human clinical trials to determine if glucosamine directly accelerates Alzheimer's progression and to identify which patients may be most vulnerable. In the meantime, experts advise that people with joint pain should consult healthcare providers and consider evidence-based alternatives like physical activity and NSAIDs, rather than relying on supplements with uncertain benefits and potential risks.